PROTACs Overcome Resistance to Cancer Therapies explores the transformative potential of proteolysis targeting chimeras (PROTACs) in addressing one of oncology’s greatest challenges: drug resistance. Edited by Dr. Daohong Zhou, this volume brings together leading experts to present the latest advances in targeted protein degradation for cancer treatment. The book covers foundational principles of PROTAC design, mechanisms of action, and their advantages over traditional small molecule inhibitors. It delves into strategies for targeting undruggable proteins, overcoming resistance in various cancer types, and mitigating emerging resistance to PROTACs.
Case studies include BCL-xL, KRAS, STAT3, and EGFR-targeting PROTACs, with insights into clinical translation and precision medicine. This resource equips cancer researchers, oncologists, and pharmaceutical scientists with practical guidance and cutting-edge knowledge. It serves as both a reference and a roadmap for developing next-generation therapeutics, making it essential for those advancing cancer drug discovery and translational medicine.
- Explains the foundational principles of targeted protein degradation and highlights how PROTACs surpass traditional small molecule inhibitors in efficacy and specificity
- Showcases diverse applications of PROTACs in targeting undruggable proteins and resistant mutations that are supported by case studies and translational research insights
- Equips researchers with methodologies for PROTAC design, optimization, and evaluation while also addressing emerging resistance mechanisms and clinical implications
